Cytokine 119 (2019) 32–36

Contents lists available at ScienceDirect

Cytokine

journal homepage: www.elsevier.com/locate/cytokine

Short communication

Inhaled delivery of Interferon-lambda restricts epithelial-derived Th2 inflammation in allergic asthma

Jina Won[a], Chan Hee Gil[a], Ara Jo[a], Hyun Jik Kim[a,b,*]

[a] Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Republic of Korea
[b] Seoul National University Hospital, Seoul, Republic of Korea

ARTICLE INFO

Keywords:
Asthma
IFN-λs
Th2 cytokines
Intranasal inhalation

ABSTRACT

The possibility has been suggested that interferon (IFN)-λs can be induced rapidly for restricting respiratory viral infection in asthmatic mice and may modulate Th2-related immune responses that underlie the pathogenesis of asthma. We sought to determine the *in vivo* contribution of IFN-λs on decrease of Th2 cytokines in the respiratory tract of *in vivo* asthma. Lungs of asthmatic mice were severely inflamed, with extensive inflammatory cell infiltration and increased goblet cell metaplasia with higher total lung resistance. The mean protein levels of TSLP and IL-33 from BAL fluid of asthmatic mice were significantly higher until 7 days. Following the collection of lung tissue of 20 asthmatic mice, TSLP and IL-33 gene expressions inversely correlated with mRNA levels of IFN-$\lambda_{2/3}$. Asthmatic mice were administered recombinant IFN-$\lambda_{2/3}$ via the intranasal route and the mRNA levels of IFN-stimulated genes were elevated to an even greater extent in the lung tissue of the mice without intranasal IFN-$\lambda_{2/3}$. Asthma-related histopathologic lung inflammation was significantly improved and total lung resistance was maintained within normal range in IFN-$\lambda_{2/3}$-treated asthmatic mice. Moreover, IFN-$\lambda_{2/3}$-treated asthmatic mice exhibited significant decrease of secreted protein levels of TSLP and IL-33 in the BAL fluid until 7 days after IFN administration. The current data provide compelling evidence that the compensation of IFN-λs can restrict the secretion of epithelial-derived Th2 cytokines, accompanied with reduced asthmatic immunopathology and IFN-λs are critical for limiting Th2-mediated allergic responses in allergic asthma.

1. Introduction

Allergic asthma is thought to arise from an imbalance in T helper type I (Th1)-Th2 immune regulation, resulting in increased levels of the Th2 cytokines interleukin (IL)-4, IL-5, and IL-13 [1]. Asthma exacerbations are acute attacks of asthma when an otherwise stable asthmatic experiences a rapid increase in symptoms accompanied by decreased lung function, most often precipitated by a respiratory viral infection [2]. Asthma exacerbations are responsible for the vast majority of the morbidity and mortality associated with asthma. Although adequate control of asthma has been achieved, better treatments are needed to reduce acute exacerbation of respiratory symptoms in asthmatics.[2]

The innate immune system of the respiratory epithelium serves as the first line of antiviral defense against invading respiratory pathogens and inhaled allergens and this system culminates in the production of interferon (IFN), a key molecule in the innate immune response. Several studies have documented abnormal immune responses to pathogens in patients with allergic asthma and dysregulation of innate immune responses against respiratory infection has been suggested to explain the higher aggravation of Th2-related inflammation of the asthmatic respiratory epithelium to allergens [3]. Strong links between low expression of type I IFNs (IFN-α and –ß), severity of allergic asthma or asthma exacerbations have been described and asthmatic patients with active disease still exhibit an inverse correlation between IFN–ß level and the severity of allergic response in the airways [3].

Recent studies showed the possibility that administration of IFNs ameliorates the asthma-related pathologic findings and Th2-induced inflammation that occur in mice after sensitization and challenge with allergens model can be reduced *in vivo* asthma with exogenous IFNs treatment [4]. Moreover, IFN–ßs might have additional properties beyond their antiviral capacity, such that they are possible antagonists of Th2-induced immune responses [5].

However, our previous study showed that IFN-λs are more predominant IFNs produced in the mouse respiratory tract to resist respiratory viral infection through enhancing the innate immune response to acute lung infection [6]. Our findings also implicated that intranasal

* Corresponding author at: Department of Otorhinolaryngology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 110-799, Republic of Korea.
E-mail address: hyunjerry@snu.ac.kr (H.J. Kim).

https://doi.org/10.1016/j.cyto.2019.02.010
Received 20 November 2018; Received in revised form 28 January 2019; Accepted 11 February 2019
Available online 09 March 2019
1043-4666/



Fig. 1. The development of allergic asthmatic mouse model and the expression of epithelial-derived Th2 cytokines. (A) The experimental protocol for development of allergic asthmatic mouse using C57BL/6. (B) Airway hyper-responsiveness was measured as methacholine-induced increases in total lung resistance (RL) in mechanically ventilated mice. Data are expressed as mean value of percentage increased from base line of the total RL ± standard deviation (SD) of five mice (White dot: OVA/OVA, Black dot:OVA/PBS). (C) BAL fluid differential counts for lymphocytes, neutrophils and eosinophils expressed as mean ± SD. (D) Histological assessment of mucus secretion in asthmatic mice. Periodic acid Schiff (PAS)-stained sections were assessed from five mice. (E) ELISA assay was performed to quantify the levels of secreted Th2 cytokines (i.e., TSLP and IL-33) in the BAL fluid of non-asthmatic and asthmatic mice until 7 days. (F) IFN-$\lambda_{2/3}$ gene expression in the lung tissue of asthmatic mice (OVA/OVA) was normalized, log transformed and correlated with gene expression of TSLP and IL-33. The data is presented as dot plots with fitted regression lines. Significant Spearman R-value is indicated (IFN-$\lambda_{2/3}$ mRNA vs TSLP: r = -0.8361, p = 0.018, IFN-$\lambda_{2/3}$ mRNA vs IL-33: r = -0.4575, p = 0.049).

application of IFN-λs may be able to control acute lung infection, regardless of the effect of IFN-α and –ß [6]. In addition, IFN-λs could be induced rapidly in asthmatic mice after IAV infection, and that this cytokine is important for restricting Th2 cytokine secretion in asthmatic mice [4]. These findings suggest the possibility that IFN-λs may modulate Th2-related immune responses that underlie the pathogenesis of asthma and can have therapeutic potential for reducing Th2 cytokines in asthmatics. To address these issues, we sought to determine the *in*

vivo contribution of IFN-λs on decrease of Th2 cytokines in the respiratory tract of asthma and found that the intranasal delivery of IFN-λs led to accelerated reduction of TSLP and IL-33, accompanied by improved Th2-mediated histopathologic findings in the lung of asthmatic mouse.

2. Material and method

Additional methodological details are available in the online supplement

2.1. Ethics statement

All experiments were approved by the Institutional Review Board of Seoul National University College of Medicine (IRB number 2015-2642) and were carried out in accordance to LABORATORY ANIMAL ACT of Korean Ministry of Food and Drug Safety for enhancing the ethics and reliability on animal testing through appropriate administration of laboratory animals and animal testing.

2.2. Allergen sensitization and challenge protocol

C57BL/6J (B6) mice (Orientalbio, Seoul, Korea) aged 7 weeks (19–23 g) were used for development of non-asthmatic and asthmatic mice. Asthma was induced by first sensitizing male B6 mice intraperitoneally (i.p.) with OVA in aluminum hydroxide and then challenging intranasally (i.n.) with soluble OVA (OVA/OVA). PBS-challenged mice (OVA/PBS) (hereafter referred to as non-asthmatic mice) were used as a negative control. Airway hyper–responsiveness (AHR) was measured in anesthetized mechanically ventilated B6 mice (Flexivent ventilator, SciReq, Montreal, Canada) at 24 h after the last intranasal OVA exposure. AHR was measured invasively using a body plethysmograph (Buxco Electronics, Inc, Wilmington, NC, USA).

2.3. Real-time PCR

Lung tissue was obtained from asthmatic mice on 1, 3, 5, and 7 days post of OVA challenge, after which total RNA was isolated using TRIzol (Invitrogen). cDNA was synthesized from 3 μg of RNA with random hexamer primers and Moloney murine leukemia virus reverse transcriptase (Perkin Elmer Life Sciences, Waltham, MA, USA and Roche Applied Science, Indianapolis, IN, USA). Target mRNA levels were quantified using target-specific primer and probe sets for mouse IFN-$\lambda_{2/3}$ (Mm04204155_gH), TSLP (Mm01157588_m1), IL-33 (Mm00505403_m1), CXCL10 (Mm00445235_m1), IFIT2 (Mm00492606_m1), Mx1 (Mm00487796_m1), and OAS2 (Mm00460961_m1). All PCR assays were quantitative and utilized plasmids containing the target gene sequences as standards.

2.4. Quantification of secreted cytokines

The levels of secreted TSLP (DY555) and IL-33 (DY3626) were quantified using a Duoset ELISA kit (R&D Systems; Minneapolis, MN, USA) according to the manufacturer's instructions for BAL fluid.

2.5. Intranasal delivery of recombinant IFN-λ2/3

To determine whether IFN-$\lambda_{2/3}$ controls Th2 inflammation in the respiratory tract of *in vivo* asthma model, asthmatic mice were exposed to whole body mainstream by the SCIREQ "InExpose" system (SCIREQ, Montreal, QB, Canada) and recombinant IFN-$\lambda_{2/3}$ (total volume of 30 ul, IFN-λ_2: 1 ug, IFN-λ_3: 1 ug) (Invitrogen, Carlsbad, CA, USA) was inoculated into asthmatic mice three times by intranasal delivery (Fig. 1a).

2.6. Immunohistochemistry and histologic analysis

Lung tissue was fixed in 10% (vol/vol) neutral buffered formalin and embedded in paraffin. Paraffin-embedded tissue slices were stained with hematoxylin/eosin (H&E) or periodic acid–Schiff (PAS) solution (Sigma, Deisenhofen, Germany). Histopathologic analysis of inflammatory cells in H&E and PAS stained lung sections was performed in a blinded fashion using a semi-quantitative scoring system as previously described [4].

2.7. Statistical analyses

Real-time PCR and ELISA results are presented as median values (interquartile ranges for 25% and 75%). The statistical significance of differences between two groups was determined by the Mann-Whitney test. Total lung resistance was also evaluated using a non-parametric test (Wilcoxon rank sum test) and the statistical correlation between TSLP, IL-33 and IFN-$\lambda_{2/3}$ was analyzed through Spearman's correlation analysis. All statistical analysis was performed with GraphPad Prism software (version 5; GraphPad Software, La Jolla, CA, USA). P values < 0.05 were considered to be statistically significant.

3. Results

3.1. A typical asthmatic phenotype of OVA-sensitized/challenged C57BL/6 (B6) mice

We found that asthmatic mice (OVA/OVA) were observed to have a significant methacholine-induced increase in total lung resistance (N = 5, Fig. 1b) and the numbers of lymphocytes, neutrophils, and eosinophils were significantly elevated in the BAL fluid of asthmatic mice (Fig. 1c). As a complementary approach, H&E- and PAS-stained micrographs of lung sections were obtained from non-asthmatic (OVA/PBS) and asthmatic mice. Histological analysis revealed that the lungs of asthmatic mice were severely inflamed, with extensive inflammatory cell infiltration at the peribronchial areas of the lung. This infiltration was accompanied by significantly increased goblet cell metaplasia (Fig. 1d). The results of ELISA showed that the mean protein levels of epithelial-derived Th2 cytokines including TSLP and IL-33 from BAL fluid of asthmatic mice were significantly higher until 7 days (Fig. 1e). As a next step, we investigated the correlation between epithelial-derived Th2 cytokines and IFN-λ mRNA levels in the lung tissue of asthmatic mice. Following the collection of lung tissue of 20 asthmatic mice (OVA/OVA), TSLP, IL-33, and IFN-$\lambda_{2/3}$ mRNA levels were measured using the cell lysate of lung tissue. Both TSLP ($r = -0.8361$, $p = 0.018$) and IL-33 ($r = -0.4575$, $p = 0.049$) gene expressions inversely correlated with mRNA levels of IFN-$\lambda_{2/3}$ in the lung of asthmatic mice (Fig. 1f). Collectively, these findings demonstrate that an allergic asthma mouse model could be established with B6 mice, and that this model could be used to investigate the therapeutic potentials of inhaled IFN-λs for reduction of epithelial-derived Th2 cytokines in asthmatic mice.

3.2. Therapeutic blockade of epithelial-derive Th2 cytokines through inhalation of IFN-λs

In the present study, we focused on new insight about the role of type III IFNs for reducing epithelial-derived Th2 cytokines in this asthmatic airway and measured the secreted protein levels of TSLP and IL-33 in asthmatic mice until 7 days after development of asthma. To comprehensively examine the type III IFN-induced innate immune responses, asthmatic mice (N = 5) were administered recombinant IFN-$\lambda_{2/3}$ via the intranasal route and the mRNA levels of ISGs (CXCL10: 1.2×10^3, IFIT2: 2.2×10^3, dMx1: 1.9×10^3, OAS2: 3.8×10^3) that are required for IFN-stimulated the innate immune response were elevated to an even greater extent in the lung tissue of the mice that



Fig. 2. Kinetics of IFN-λ-inoculated asthmatic mice. Asthmatic mice (OVA/OVA, N = 5) were exposed to whole body mainstream by the SCIREQ "InExpose" system and recombinant IFN-$\lambda_{2/3}$ (total volume of 30 ul, IFN-λ_2: 1 ug, IFN-λ_3: 1 ug) were inoculated to asthmatic mice. (A) mRNA levels of IFN-stimulated genes such as CXCL10, IFIT2, Mx1, and OAS2 were measured using real-time PCR. (B) Histological assessment for Hematoxylin and eosin (H&E)- and PAS-staining lung sections of asthmatic mice was performed after recombinant IFN-λ inoculation by intranasal delivery. (C) Total lung resistance was determined in recombinant IFN-λ-inoculated asthmatic mice and data are expressed as mean value of percentage increased from base line of the total RL ± standard deviation (SD) of five mice (White dot: OVA/OVA, Black dot:OVA/PBS). (D) ELISA assay was performed to quantify the levels of secreted TSLP and IL-33 levels in the BAL fluid of recombinant IFN-λ-inoculated asthmatic mice. Micrographs shown are representative of lung sections from five mice. PCR, plaque assay, and multiplex assay results are presented as mean ± SD from five independent experiments (*, $p < 0.05$ compared with the levels of IFN-λs-inoculated asthmatic mice).

received intranasal IFN-$\lambda_{2/3}$ (CXCL10: 6.2×10^4, IFIT2: 6.8×10^4, dMx1: 7.8×10^4, OAS2: 7.1×10^4, Fig. 2a).

To determine whether inhaled administration of IFN-$\lambda_{2/3}$ reduces Th2 inflammation in asthmatic airway, asthmatic mice (N = 5) were administered recombinant IFN-$\lambda_{2/3}$ via the intranasal route. Interestingly, IAV-mediated histopathologic lung inflammation was significantly improved and methacholine-induced increase of total lung resistance was not observed in IFN-$\lambda_{2/3}$-treated asthmatic mice (Fig. 2b and c). Moreover, IFN-$\lambda_{2/3}$-treated asthmatic mice exhibited significant decrease of secreted protein levels of TSLP and IL-33 in the BAL fluid until 7 days after IFN-$\lambda_{2/3}$ administration (Fig. 2d). The current findings support the idea that significant induction of epithelial-derived Th2 promoting cytokines in asthmatic mice could be suppressed through inhaled administration of IFN-λs although strong correlation between induction of epithelial-derived Th2 cytokines and lower expression of IFN-λs was observed in the airway of asthmatic mice.

4. Discussion

The present study provides a distinctive role of IFN-related innate immune system for limitation of Th2-mediated allergic responses in the asthmatic airway and the significant reduction of epithelial-derived Th2 cytokines through the inhaled delivery of IFN-λs. Here, we showed that inhaled administration of IFN-$\lambda_{2/3}$ led to restrict Th2 cytokine secretion

such as TSLP and IL-33 in asthmatic mice and our findings also imply that exogenous compensation of IFN-λs is a potential strategy for controlling the Th2-mediated allergic responses of asthmatic mice at the level of respiratory epithelium.

Asthma is a heterogenous inflammatory disorder of the lung caused principally by sensitization and exposure to an allergens and asthma exacerbation is responsible for vast majority of the morbidity and mortality associated with asthma [1,2]. To the best of our knowledge, deficient innate immune responses (including reduced induction of IFNs) are expected in the asthmatic respiratory tract [3] and the experiments performed here also showed that asthmatic mice exhibited a significantly induction of TSLP and IL-33 in the BAL fluid, accompanied by impaired production of IFN-λs. Additional research aiming to understand the mechanisms driving these deficient innate immune responses is urgently required to reduce the asthma exacerbation and such studies are necessary for identifying novel targets for the development of effective therapies against Th2-related inflammation in asthmatics [7,8]. Our study focused on the influence of IFN-related innate immune responses in respiratory epithelium to suppress Th2-mediated allergic responses in asthma and we found that inhaled delivery of IFN-λs led to reduced Th2-related immune responses, including decreased TSLP and IL-33 secretion. Moreover, resolution of extensive asthma-related lung pathologies was observed and metacholline-induced total lung resistance was completely improved in IFN-λs -treated asthmatic mice.

We speculated that the therapeutic effect of IFN-λs against allergic responses is restricted to the upper and lower respiratory tracts, which contain high percentages of epithelial cells that express the IFN-λ receptor [9]. Therefore, the inhaled delivery of IFN-λs and induction of IFN-stimulated genes' transcription more effectively suppressed epithelial-derived Th2 cytokines secretion in asthmatic respiratory tract. Recently, IFN-λs were also found to act on non-hematopoietic cells to control viral infection and the regulation of adaptive immune response *in vivo* lung tissue, indicating that the anti-inflammatory mechanism against Th2 cytokines of IFN-λs is direct to the respirator epithelium of asthmatic lung [4]. In addition, the aggravation of asthma increases might be exponentially related with a higher risk of respiratory viral infection and is a leading cause of the morbidity and mortality in asthmatics [2]. Our data suggest the possibility that the treatment of IFN-λs and induction of ISGs can control acute viral lung infection in asthmatics and IFN-λs are also a promising new target to prevent the risk of exacerbation in asthma or higher mortality of asthmatics.

Taken together, the current data provide compelling evidence that the compensation of IFN-λs can restrict the secretion of epithelial-derived Th2 cytokines, accompanied with reduced asthmatic immunopathology and IFN-λs are critical for limiting Th2-mediated allergic responses in allergic airway disease. Therefore, strategies involving the compensation or maintenance of IFN-λs are new opportunities for invoking an effective control of allergic asthma.

5. Competing financial interests

The authors declare no competing financial interests.

Acknowledgements

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, (2016R1D1A1B01014116) (H.J.K.). It was also supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C2923, HI18C1337 to H.J.K).

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cyto.2019.02.010.

References

[1] M. Kubo, Innate and adaptive type 2 immunity in lung allergic inflammation, Immunol. Rev. 278 (2017) 162–172.
[2] J.R. Castillo, S.P. Peter, W.W. Busse, Asthma exacerbations: pathogenesis, prevention, and treatment, J. Allergy. Clin. Immunol. Pract. 5 (2017) 918–927.
[3] D.A. Patel, Y. You, G. Huang, D.E. Byers, H.J. Kim, E. Agapov, et al., Interferon response and respiratory virus control are preserved in bronchial epithelial cells in asthma, J. Allergy Clin. Immunol. 134 (2014) 1402–1412 e7.
[4] S. An, Y.J. Jeon, A. Jo, H.J. Lim, Y.E. Han, S.W. Cho, et al., Initial influenza virus replication can be limited in allergic asthma through rapid induction of type III interferons in respiratory epithelium, Front. Immunol. 9 (2018) 986.
[5] C.U. Duerr, C.D. McCarthy, B.C. Mindt, M. Rubio, A.P. Meli, J. Pothlichet, et al., Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells, Nat. Immunol. 17 (2016) 65–75.
[6] S. Kim, M.J. Kim, C.H. Kim, J.W. Kang, H.K. Shin, D.Y. Kim, et al., The Superiority of IFN-λ as a therapeutic candidate to control acute influenza viral lung infection, Am. J. Respir. Cell. Mol. Biol. 56 (2017) 202–212.
[7] M. Contoli, S.D. Message, V. Laza-Stanca, M.R. Edwards, P.A. Wark, N.W. Bartlett, et al., Role of deficient type III interferon-lambda production in asthma exacerbations, Nat. Med. 12 (2006) 1023–1026.
[8] O. Koltsida, M. Hausding, A. Stavropoulos, S. Koch, G. Tzelepis, C. Ubel, et al., IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease, EMBO. Mol. Med. 3 (2011) 348–361.
[9] A. Lasfar, W. Abushahba, M. Balan, K.A. Cohen-Solal, Interferon lambda: a new sword in cancer immunotherapy, Clin. Dev. Immunol. 2011 (2011) 349575.